Nutrien Ltd. Q2 FY26 Earnings Analysis
Published 29 May 2026 | Chemicals | Market Cap: ₹33.6K Cr
Price
₹69.65
Market Cap
₹33.6K Cr
P/E Ratio
14.2
Revenue Rank
Margin Rank
Earnings Summary
- Nutrein maintains full-year guidance with expected sales volumes of potash at 14.1 to 14.8 million tonnes and nitrogen at 9.2 to 9.7 million tonnes for 2026. - Nutrien maintains full-year guidance with confidence, supported by strong Q1 performance and ongoing operational excellence.
📊 Revenue & Sales Performance
Rank 3- Nutrein maintains full-year guidance with expected sales volumes of potash at 14.1 to 14.8 million tonnes and nitrogen at 9.2 to 9.7 million tonnes for 2026. - Strong global demand supports sustaining or increasing sales, with potash shipments forecasted between 74 to 77 million tonnes, indicating potential growth beyond last year's 74.5 million tonnes. - High single-digit growth anticipated in proprietary products gross margin, driven by new product launches and expansion in core retail geographies including the U.S., Australia, and international markets. - Retail business remains constructive with maintained EBITDA guidance of $1.75 to $1.95 billion for 2026, supported by strong customer engagement and expanding proprietary products. - Growth is partly driven by crop nutrient replenishment needs following a large 2025 corn and soybean harvest and increased acres planted in key markets. - Ongoing strategic reviews and portfolio optimization, including potential sales in certain business segments, aim to strengthen core growth areas.
📈 Profitability & Margins
Rank 3- Nutrien maintains full-year guidance with confidence, supported by strong Q1 performance and ongoing operational excellence. - High single-digit growth expected in proprietary products gross margin in 2026 due to new product launches, increased demand, and international expansion. - No major changes anticipated in margin expectations across product segments except some pressure on phosphate margins in Q2 due to elevated input costs. - The company is constructive on potash demand and expects shipment range of 74-77 million tonnes in 2026, testing global logistics and production capacity. - Nitrogen segment benefits from higher global benchmarks and low-cost production, driving strong adjusted EBITDA. - Retail adjusted EBITDA guidance remains $1.75 billion to $1.95 billion with strong customer engagement during planting season. - Nutrien is focused on cost management, asset optimization, and capital allocation to sustain structural free cash flow growth and returns. - Overall, market conditions and strategic initiatives support positive earnings outlook and stable profitability for 2026.
🏗️ Capital Expenditure Plans
Yes- **2026 Capital Expenditures Guidance:** Maintained at $2 billion to $2.1 billion. - **Strategic Reviews:** - Phosphate business: Completing detailed assessment of assets and configurations; progressing a sale process with significant initial expressions of interest. - Trinidad nitrogen operations: Evaluating all strategic options, including potential sale, focused on strengthening core North American assets. - Brazilian business: Reviewing components and commenced sales process for Brazilian soybean seed business, expected to complete in H2 2026. - **Capital Allocation:** Continuing share repurchases at approximately $55 million per month in Q2 2026. - **Investment Focus:** Simplifying the business, strengthening core asset base, improving capital efficiency to drive structural free cash flow growth and sustainable returns.
💰 Fundraising & Capital Structure
No information- The company completed share repurchases of approximately $550 million last year and reduced adjusted net debt by approximately $600 million. - In 2026, they plan to continue share repurchases on a ratable basis with a pace of approximately $55 million per month so far in the second quarter. - They see opportunities to further strengthen the balance sheet in 2026. - There is no explicit mention of new fundraising through debt or equity during the call. - The focus remains on consistent capital allocation, optimizing the portfolio, and maintaining a strong balance sheet.
📋 Order Book & Pipeline
No informationThe provided pages do not explicitly state current or expected orderbook or pending orders in numeric terms. However, relevant insights include: - Prior to the Middle East conflict, approximately 35% of second quarter planned nitrogen sales volumes were committed, similar to the prior year. - Canpotex (potash exporter) is fully committed through the end of June. - For nitrogen, sales volume guidance remains 9.2 to 9.7 million tonnes with planned turnarounds at 3 facilities in 2026. - Retail inventories are expected to be very empty towards the end of spring, indicating anticipated refill orders. - Strong customer engagement and product movement have been reported thus far into 2026. - Inventory remains short due to ongoing Middle East disruptions, impacting over 30% of global urea trade and 25% of ammonia and phosphate. - Market remains tight with supply-demand fundamentals expected to keep pricing and demand elevated near term. No exact numerical order backlog or pending order values provided.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Nutrien Ltd. Q2 FY26 results?
- Nutrein maintains full-year guidance with expected sales volumes of potash at 14.1 to 14.8 million tonnes and nitrogen at 9.2 to 9.7 million tonnes for 2026. - Nutrien maintains full-year guidance with confidence, supported by strong Q1 performance and ongoing operational excellence.
What is Nutrien Ltd. share price analysis?
Nutrien Ltd. currently shows a below-average growth signal. The stock trades at a P/E of 14.2 with a market cap of $33,569. Investors should review the full earnings analysis for detailed insights.
Is Nutrien Ltd. planning capital expenditure?
- **2026 Capital Expenditures Guidance:** Maintained at $2 billion to $2.1 billion.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
